Bain J, Rachlis V, Robert E, Khait Z
Contraception. 1980 Apr;21(4):365-79. doi: 10.1016/s0010-7824(80)80015-1.
A male contraceptive trial was undertaken in 23 men using a combination of oral medroxyprogesterone acetate (MPA) and oral methyltestosterone (MeT). The men were divided into four groups according to varying drug dosages and were followed for 15 months (control - 3 months, treatment - 6 months, follow-up - 6 months). The parameters assessed included sperm count and motility, serum gonadotropins and sex steroids, and several biochemical and hematological tests. A questionnaire dealing with side-effects and changes in sexual function was administered intermittently. Although sperm count was suppressed (most dramatically at the highest drug doses, MPA 20mg,MeT 20mg), it was not suppressed to infertile levels. Sperm motility was unaltered; LH was modestly suppressed, FSH was not suppressed; testosterone was suppressed even at low doses; dihydrotestosterone responses were inconsistent. No significant biochemical abnormalities or side-effects occurred although some men experienced mild transient acne, gynecomastia and decreased testicular size. We conclude that in the doses used in this trial, the combination of MPA and MeT is not effective for male contraceptive, purposes and that higher doses may induce severe and undesirable side-effects.
一项针对23名男性的男性避孕试验采用了口服醋酸甲羟孕酮（MPA）和口服甲基睾酮（MeT）的联合用药方式。这些男性根据不同的药物剂量被分为四组，并接受了15个月的随访（对照组 - 3个月，治疗组 - 6个月，随访组 - 6个月）。评估的参数包括精子数量和活力、血清促性腺激素和性类固醇，以及多项生化和血液学检查。一份关于副作用和性功能变化的问卷被间歇性地发放。尽管精子数量受到了抑制（在最高药物剂量MPA 20mg、MeT 20mg时最为显著），但并未被抑制到不育水平。精子活力未改变；促黄体生成素（LH）受到适度抑制，促卵泡生成素（FSH）未受抑制；睾酮即使在低剂量时也受到抑制；双氢睾酮的反应不一致。尽管一些男性出现了轻度短暂性痤疮、乳腺增生和睾丸尺寸减小，但未出现显著的生化异常或副作用。我们得出结论，在本试验所使用的剂量下，MPA和MeT的联合用药对男性避孕无效，且更高剂量可能会引发严重且不良的副作用。
